Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
29.92USD
9:00pm BST
29.92USD
9:00pm BST
Change (% chg)
$-0.04 (-0.13%)
$-0.04 (-0.13%)
Prev Close
$29.96
$29.96
Open
$30.01
$30.01
Day's High
$30.10
$30.10
Day's Low
$29.52
$29.52
Volume
186,575
186,575
Avg. Vol
131,158
131,158
52-wk High
$30.24
$30.24
52-wk Low
$11.45
$11.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Mar '19 | 0.00 | -0.874 |
| FY 2018 | Dec '18 | 0.00 | -0.648 |
| Sep '18 | 0.00 | -0.640 | |
| Jun '18 | 0.00 | -0.609 | |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-19 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-19 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-19 | 5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Sep-19 | 5 | -0.79 | -0.69 | -0.88 | -0.61 |
| Quarter Ending Dec-19 | 5 | -0.80 | -0.68 | -0.92 | -0.66 |
| Year Ending Dec-19 | 6 | -3.18 | -2.90 | -3.51 | -2.13 |
| Year Ending Dec-20 | 5 | -3.43 | -2.80 | -3.91 | -2.42 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 29.73 | 33.85 | |
| P/E High - Last 5 Yrs. | -- | 47.56 | 54.29 | |
| P/E Low - Last 5 Yrs. | -- | 27.30 | 28.22 | |
| Beta | -- | 1.00 | 0.99 | |
| Price to Sales (TTM) | -- | 6.00 | 7.90 | |
| Price to Book (MRQ) | 8.09 | 3.84 | 4.38 | |
| Price to Tangible Book (MRQ) | 8.09 | 4.14 | 5.07 | |
| Price to Cash Flow (TTM) | -- | 21.62 | 23.70 | |
| % Owned Institutions | 66.11 | 0.79 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.83 | 1.67 | |
| Dividend Yield - 5 Year Avg | -- | 1.47 | 1.37 | |
| Dividend 5 Year Growth Rate | -- | 6.74 | 6.82 | |
| Payout Ratio(TTM) | -- | 50.64 | 46.67 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 13.42 | 14.65 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 6.45 | 8.45 | |
| Sales - 5 Yr. Growth Rate | -- | 8.32 | 9.43 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -102.36 | 18.49 | 19.40 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -115.90 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 5.66 | 7.15 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 7.02 | 8.01 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.52 | 2.52 |
| Current Ratio (MRQ) | 15.23 | 3.55 | 3.52 |
| LT Debt to Equity (MRQ) | 2.97 | 11.64 | 12.61 |
| Total Debt to Equity (MRQ) | 2.97 | 16.17 | 17.64 |
| Interest Coverage (TTM) | -119.74 | 7.61 | 14.93 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 51.41 | 50.25 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.53 | 51.36 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 17.64 | 16.42 | |
| Operating Margin (TTM) | -- | -2.19 | -6.97 | |
| Operating Margin - 5 Yr. Avg. | -- | 13.94 | 11.87 | |
| Pre-Tax Margin (TTM) | -- | -2.50 | -7.30 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 18.73 | 15.72 | |
| Net Profit Margin (TTM) | -- | -6.21 | -11.11 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 14.06 | 11.11 | |
| Effective Tax Rate (TTM) | -- | 20.27 | 20.61 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.92 | 24.51 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 1,012,949,194 | 870,638,159 | |
| Net Income/Employee (TTM) | -1,797,015 | 118,477,208 | 101,855,832 | |
| Receivable Turnover (TTM) | -- | 5.61 | 5.88 | |
| Inventory Turnover (TTM) | -- | 2.59 | 3.66 | |
| Asset Turnover (TTM) | 0.00 | 0.88 | 0.85 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -64.93 | 10.57 | 10.25 | |
| Return on Assets - 5 Yr. Avg. | -71.76 | 11.70 | 11.17 | |
| Return on Investment (TTM) | -68.89 | 13.04 | 12.69 | |
| Return on Investment - 5 Yr. Avg. | -76.64 | 14.80 | 14.15 | |
| Return on Equity (TTM) | -88.38 | 14.12 | 17.13 | |
| Return on Equity - 5 Yr. Avg. | -291.97 | 15.92 | 15.53 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -126.36 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 13.50 | 10.34 | 99 | 47 |
| 13 Week | 42.45 | 38.40 | 99 | 34 |
| 26 Week | 110.70 | 85.55 | 99 | 15 |
| 52 Week | 66.24 | 55.89 | 99 | 66 |
| YTD | 118.04 | 80.64 | 99 | 20 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 66.11% |
| # of Holders: | 148 |
| Total Shares Held: | 41,804,365 |
| 3 Mo. Net Change: | 116,986 |
| # New Positions: | 7 |
| # Closed Positions: | 0 |
| # Increased Positions: | 16 |
| # Reduced Positions: | 3 |
| # Net Buyers: | 13 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.